Hangzhou Alltest Biotech Co., Ltd.

Shanghai Stock Exchange 688606.SS

Hangzhou Alltest Biotech Co., Ltd. Price to Book Ratio (P/B) on January 14, 2025: 1.31

Hangzhou Alltest Biotech Co., Ltd. Price to Book Ratio (P/B) is 1.31 on January 14, 2025, a -3.74% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Hangzhou Alltest Biotech Co., Ltd. 52-week high Price to Book Ratio (P/B) is 1.57 on April 26, 2024, which is 19.31% above the current Price to Book Ratio (P/B).
Hangzhou Alltest Biotech Co., Ltd. 52-week low Price to Book Ratio (P/B) is 0.95 on July 04, 2024, which is -27.48% below the current Price to Book Ratio (P/B).
Hangzhou Alltest Biotech Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 1.25.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 688606.SS

Hangzhou Alltest Biotech Co., Ltd.

CEO	Mr. Fei Gao
IPO Date	March 25, 2021
Location	China
Headquarters	#550, Yinhai Street
Employees	1,093
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and market of in vitro diagnostic reagents worldwide. It offers rapid diagnostic products, including women's health, infectious diseases, drugs, cancer, cardiovascular, and other five series of products. The company is based in Hangzhou, China.

Key trends

Past 5 years